Patent 9381173 was granted and assigned to Novaremed on July, 2016 by the United States Patent and Trademark Office.
Isolated stereoisomeric forms of the compound (S)2-N(3-O-(propan 2-ol) -1-propyl-4-hydroxybenzene)-3-phenylpropylamide and uses in the treatment of pain.